Johnson & Johnson plans to start human testing of its experimental coronavirus vaccine by September and make it ready for emergency use in early 2021, the drugmaker said on Monday.
J&J also committed more than $1 billion of investment along with U.S. agency Biomedical Advanced Research and Development Authority (BARDA) to co-fund vaccine research, expanding a previous collaboration.
Global efforts are underway to develop a vaccine for the virus that has killed over 34,000 worldwide, but experts have cautioned it could take over a year to have a vaccine ready.
Early-Stage Trial
A patient was dosed with Moderna Inc's vaccine in an early-stage trial earlier this month, making it the front-runner in the race to develop a viable vaccine.
J&J said in January it had begun working on a possible vaccine for the coronavirus, using the same technologies used to make its experimental Ebola vaccine.
News by Reuters, edited by Donna Ahern Checkout. Click subscribe to sign up for the Checkout print edition.
